Distinguished in Rheumatoid Arthritis (RA)

Dr. Vishala L. Chindalore

Rheumatology
Anniston Medical Clinic PC
1010 Christine Ave, 
Anniston, AL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Distinguished in Rheumatoid Arthritis (RA)
Anniston Medical Clinic PC
1010 Christine Ave, 
Anniston, AL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vishala Chindalore is a Rheumatologist in Anniston, Alabama. Dr. Chindalore and is rated as a Distinguished provider by MediFind in the treatment of Rheumatoid Arthritis (RA). Their top areas of expertise are Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Fibromyalgia, and Rhizomelic Pseudopolyarthritis. Dr. Chindalore is currently accepting new patients.

Their clinical research consists of co-authoring 10 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 7 articles and participated in 3 clinical trials in the study of Rheumatoid Arthritis (RA).

Specialties
Rheumatology
Licenses
Internal Medicine in AL
Hospital Affiliations
Northeast Alabama Regional Medical Center
Languages Spoken
English

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AmeriHealth
  • EPO
  • HMO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions

Accepted plan types not found. Please verify directly with the provider.

CareSource
  • HMO
Centene

Accepted plan types not found. Please verify directly with the provider.

Cigna
  • EPO
  • HMO
  • PPO
Clear Spring Health

Accepted plan types not found. Please verify directly with the provider.

CVS Health

Accepted plan types not found. Please verify directly with the provider.

Devoted Health

Accepted plan types not found. Please verify directly with the provider.

Elixir

Accepted plan types not found. Please verify directly with the provider.

Farm Bureau Health Plans

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid

Accepted plan types not found. Please verify directly with the provider.

Medicaid

Accepted plan types not found. Please verify directly with the provider.

Meridian Choice

Accepted plan types not found. Please verify directly with the provider.

Mutual of Omaha

Accepted plan types not found. Please verify directly with the provider.

Oscar
  • EPO
  • HMO
  • PPO
Primewell Health Services

Accepted plan types not found. Please verify directly with the provider.

Silverscript

Accepted plan types not found. Please verify directly with the provider.

UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health

Accepted plan types not found. Please verify directly with the provider.

Walgreens

Accepted plan types not found. Please verify directly with the provider.

WellCare Health Plans

Accepted plan types not found. Please verify directly with the provider.

View 21 Less Insurance Carriers -

Locations

ANNISTON MEDICAL CLINIC PC
1010 Christine Ave, Anniston, AL 36207

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Multipart Exploratory Study to Evaluate Splenic Nerve Stimulation in Patients With Rheumatoid Arthritis
Multipart Exploratory Study to Evaluate Splenic Nerve Stimulation in Patients With Rheumatoid Arthritis
Enrollment Status: Recruiting
Publish Date: May 22, 2024
Intervention Type: Drug, Device
Study Phase: Not Applicable
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of VIB1116 in Conventional Dendritic Cell (cDC) and Plasmacytoid Dendritic Cell (pDC)-Mediated Rheumatic Diseases
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of VIB1116 in Conventional Dendritic Cell (cDC) and Plasmacytoid Dendritic Cell (pDC)-Mediated Rheumatic Diseases
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus
A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Drug
Study Drug: TAK-079
Study Phase: Phase 1
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Randomized, Placebo-Controlled, Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Patients With Systemic Lupus Erythematosus
A Phase 1, Randomized, Placebo-Controlled, Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: March 04, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

10 Total Publications

A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
Journal: Arthritis research & therapy
Published: December 21, 2023
Similar Doctors
Kenneth G. Saag
Distinguished in Rheumatoid Arthritis (RA)
Dr. Kenneth G. Saag
Rheumatology
Distinguished in Rheumatoid Arthritis (RA)
Dr. Kenneth G. Saag
Rheumatology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (57.1 mi)
205-934-3460
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kenneth Saag is a Rheumatologist in Birmingham, Alabama. Dr. Saag and is rated as an Elite provider by MediFind in the treatment of Rheumatoid Arthritis (RA). His top areas of expertise are Gout, Osteoporosis, Postmenopausal Osteoporosis, and Arthritis. Dr. Saag is currently accepting new patients.

Distinguished in Rheumatoid Arthritis (RA)
Dr. Maria I. Danila
Rheumatology
Distinguished in Rheumatoid Arthritis (RA)
Dr. Maria I. Danila
Rheumatology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (57.3 mi)
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Maria Danila is a Rheumatologist in Birmingham, Alabama. Dr. Danila and is rated as a Distinguished provider by MediFind in the treatment of Rheumatoid Arthritis (RA). Her top areas of expertise are Rheumatoid Arthritis (RA), Osteoporosis, Arthritis, and Sjogren Syndrome. Dr. Danila is currently accepting new patients.

Distinguished in Rheumatoid Arthritis (RA)
Dr. Angela O. Pham
Rheumatology
Distinguished in Rheumatoid Arthritis (RA)
Dr. Angela O. Pham
Rheumatology

Tanner Medical Group Inc

905 Dixie St, 
Carrollton, GA 
 (43.7 mi)
770-812-3631
Languages Spoken:
English, Filipino, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Angela Pham is a Rheumatologist in Carrollton, Georgia. Dr. Pham and is rated as an Advanced provider by MediFind in the treatment of Rheumatoid Arthritis (RA). Her top areas of expertise are Rheumatoid Arthritis (RA), Psoriatic Arthritis, Psoriasis, and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections. Dr. Pham is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chindalore's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile